Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

NCT03737968 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Stage II-IVB Operable HNSCC Oral Cavity
Hypopharynx
Oropharynx
Larynx

Interventions

DRUG: Durvalumab
DRUG: durvalumab + tremelimumab

Sponsor

Yonsei University